The discovery that TAM respond to anti-PD-1/PD-L1 therapy, which both boosts their phagocytic activity and activation to restore their anti-tumor function and potentially influences T cell responses to immunotherapy, is crucial for enhancing and optimizing cancer immunotherapy [82,83]. The gene discussed is PDCD1; the disease is cancer.